A turning point for interlocutory injunctions in patent cases
The Federal Court of Australia recently dismissed an application for an interlocutory injunction made by the sanofi-aventis group against Hospira and Interpharma. This has allowed Hospira and Interpharma to launch generic versions of the oncology drug docetaxel as planned, pending the outcome of a full trial. Justice Jagot’s decision is significant because in recent years most applications for an interlocutory injunction in pharmaceutical and medical device patent cases have been successful. Mallesons represented Hospira in this litigation. You can read more about the case in our alert here.